CatalYm’s efforts to revive obesity target for solid tumors yield positive PhIIa results

CatalYm’s solid tumor candidate, which targets a protein previously explored in obesity, has boosted responses in combination with an immune checkpoint inhibitor in an early-stage trial. The results pave the way for the next stage of controlled studies in earlier lines of disease.

The Phase IIa Click here to view original post